# Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?

> **NCT04623385** · PHASE4 · UNKNOWN · sponsor: **Kafrelsheikh University** · enrollment: 1000 (estimated)

## Conditions studied

- Covid19

## Interventions

- **COMBINATION_PRODUCT:** Aerosolized 13 cis retinoic acid plus Inhalation Inhaled testosterone
- **DRUG:** The standard therapy

## Key facts

- **NCT ID:** NCT04623385
- **Lead sponsor:** Kafrelsheikh University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-11
- **Primary completion:** 2020-12
- **Final completion:** 2021-12
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2020-11-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04623385

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04623385, "Clinical Role of Testosterone and Dihydrotestosterone and Which of Them Should be Inhibited in COVID-19 Patients - A Double-edged Sword?". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04623385. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*